Stoppe Christian, McDonald Bernard, Benstoem Carina, Elke Gunnar, Meybohm Patrick, Whitlock Richard, Fremes Stephen, Fowler Robert, Lamarche Yoan, Jiang Xuran, Day Andrew G, Heyland Daren K
Department of Anesthesiology, University Hospital RWTH Aachen, Aachen, Germany;; Department of Thoracic, Cardiac, and Vascular Surgery, University Hospital, RWTH Aachen, Aachen, Germany;.
Division of Cardiac Anesthesiology and Critical Care Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;
J Cardiothorac Vasc Anesth. 2016 Jan;30(1):30-8. doi: 10.1053/j.jvca.2015.07.035. Epub 2015 Jul 29.
Validated composite outcomes after complicated cardiac surgery are poorly established. Therefore, the authors evaluated a novel composite endpoint, persistent organ dysfunction (POD)+death, which is defined as any need for life-sustaining therapies or death at any time within 28 days from surgery.
Secondary analysis extracted from a large-scale prospective randomized trial of critically ill cardiac surgery patients.
Multi-institutional, university hospitals.
Ninety-five cardiac surgery patients with complicated postoperative courses.
Cardiac surgery with cardiopulmonary bypass.
At 28 days following surgery, the prevalence of POD was 15%, and 23% of patients had died (POD+death = 38%). Patients alive with POD at day 28 exhibited a significantly higher extent of organ injury and longer ICU (33 v 7 days; p<0.001) and hospital lengths of stay (49 v 21 days; p<0.001) compared to patients without POD at day 28. At 3 and 6 months, quality-of-life scores (by Short Form 36 questionnaire) showed a significantly reduced rating for most components in patients with POD at day 28 compared to those without POD. The 6-month mortality rate was 21% among patients alive with POD at day 28 compared to 5% among patients alive without POD (p = 0.05). The calculated number of patients needed per arm to detect a 25% relative risk reduction for mortality alone was 762 compared to 386 per arm for POD+ death.
POD+death at day 28 following cardiac surgery may be a valid composite endpoint and offers statistical efficiencies in terms of sample size calculations for cardiac surgical trials.
复杂心脏手术后经过验证的综合结局尚未完全确立。因此,作者评估了一种新的综合终点,即持续性器官功能障碍(POD)加死亡,其定义为术后28天内任何时间需要维持生命的治疗或死亡。
从一项针对重症心脏手术患者的大规模前瞻性随机试验中提取的二次分析。
多机构大学医院。
95例术后病程复杂的心脏手术患者。
体外循环心脏手术。
术后28天,POD的发生率为15%,23%的患者死亡(POD加死亡=38%)。与28天时无POD的患者相比,28天时存活且有POD的患者器官损伤程度明显更高,ICU住院时间更长(33天对7天;p<0.001),住院时间也更长(49天对21天;p<0.001)。在3个月和6个月时,生活质量评分(通过简短健康调查问卷36项)显示,与无POD的患者相比,28天时患有POD的患者大多数项目的评分显著降低。28天时存活且有POD的患者6个月死亡率为21%,而无POD的存活患者为5%(p = 0.05)。仅检测死亡率相对风险降低25%时,每组所需的患者数量计算为762例,而POD加死亡每组为386例。
心脏手术后28天的POD加死亡可能是一个有效的综合终点,并且在心脏手术试验的样本量计算方面具有统计效率。